Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science Holding's revenue for the
six
months ended in Dec. 2025 was $1.07 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $2.20 Mil.
SL Science Holding's Revenue per Share for the
six
months ended in Dec. 2025 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.
Warning Sign:
SL Science Holding Ltd revenue per share is in decline over the past 12 months.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
SL Science Holding Revenue Related Terms
SL Science Holding Revenue Historical Data
* Premium members only.
The historical data trend for SL Science Holding's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding Revenue Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
Revenue
0.88
3.36
2.20
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Revenue
0.00
1.22
2.14
1.13
1.07
SLBT vs DMRA, BCAX, TYRA: Revenue Comparison
For the Biotechnology subindustry, SL Science Holding's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's Revenue distribution charts can be found below:
* The bar in red indicates where SL Science Holding's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding (SLBT) has a Revenue of $2.20 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on SL Science Holding and its competitors.
Is SL Science Holding's Revenue too high?
SL Science Holding's current Revenue is $2.20 Mil. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's Revenue compare to DMRA and BCAX?
SL Science Holding's Revenue of $2.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on SL Science Holding and its competitors. SL Science Holding's current Revenue is $2.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current Revenue of $2.20 Mil. The current Revenue is $2.20 Mil. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For SL Science Holding (SLBT), the current Revenue is $2.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
